iBio Expands COVID-19 Vaccine Collaboration to Include the Infectious Disease Research Institute
April 09 2020 - 07:30AM
iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a
biologics contract manufacturing organization and biotechnology
innovator, today announced the signing of two Master Services
Agreements (the MSAs”) and a Memorandum of Understanding (the
“MoU”) with the Infectious Disease Research Institute (“IDRI”) in
support of iBio’s SARS-CoV-2 Virus-Like Particle (“VLP”) vaccine
development.
Under the MSAs, IDRI will support pre-clinical
development and provide clinical trial oversight, while iBio will
provide process development and manufacturing services to IDRI, as
needed. Additionally, the MoU calls for iBio and IDRI to establish
a separate, additional agreement within the next 60 days if the
Company opts to include one of IDRI’s novel adjuvants in the
COVID-19 vaccine development program (“IBIO-200”). The MSAs and the
MoU integrate IDRI into iBio’s collaboration with the Texas A&M
University System to create a strong partnership that brings deep
experience and advanced technologies and capabilities to the task
of moving IBIO-200 into the clinic.
“We are delighted to have IDRI contribute its
deep understanding of infectious diseases and vaccine development
expertise to the team,” said Tom Isett, Co-Chairman & Chief
Executive Officer of iBio. “We are also looking forward to
evaluating the novel adjuvants in IDRI’s portfolio that may deliver
even greater immunostimulatory effects. A more potent
antigen-adjuvant combination would further increase our projected
manufacturing capacity for production of a vaccine for COVID-19
disease.”
“We are excited to be a partner in the
development of IBIO-200,” said Corey Casper, M.D., MPH, Chief
Executive Officer of the IDRI and Clinical Professor of Medicine
and Global Health at the University of Washington. “Combining
iBio’s VLP antigen with an IDRI adjuvant provides for promising
safety and efficacy characteristics, and importantly, the ready
ability to scale-up manufacturing to help meet the projected global
demand for a suitable vaccine.”
About iBio, Inc.
iBio is a global leader in plant-based biologics
manufacturing. Its FastPharming System™ combines
vertical farming, automated hydroponics, and glycan engineering
technologies to rapidly deliver gram quantities of high-quality
monoclonal antibodies, vaccines, bioinks and other proteins. The
Company’s subsidiary, iBio CDMO LLC, provides
FastPharming Contract Development and
Manufacturing Services via its 130,000 square foot facility in
Bryan, Texas. Originally built in 2010 with funding from the U.S.
Defense Advanced Research Projects Agency (DARPA), iBio’s
FastPharming Facility was part of the “Blue Angel”
initiative to establish factories capable of rapid delivery of
medical countermeasures in response to a disease pandemic. iBio’s
FastGlycaneering Development Service™ includes an
array of new glycosylation technologies for engineering
high-performance recombinant proteins. Additionally, iBio is
developing proprietary products which include IBIO-100 for the
treatment of fibrotic diseases and IBIO-200, a COVID-19 vaccine.
For more information, visit www.ibioinc.com.
About the Infectious Disease Research
Institute As a nonprofit global health organization, IDRI
(Infectious Disease Research Institute) takes a comprehensive
approach to combat infectious diseases, combining the high-quality
science of a research organization with the product development
capabilities of a biotech company to create vaccines and
therapeutics. IDRI combines passion for improving human health with
the understanding that it is not just what our scientists know
about disease, but what we do to change its course that will have
the greatest impact. Founded in 1993, IDRI has 55 employees
headquartered in Seattle with more than 100 partners/collaborators
around the world. For more information,
visit www.idri.org.
About The Texas A&M University
System
TAMUS is one of the largest systems of higher
education in the nation with a budget of $6.3 billion. The System
is a statewide network of 11 universities; a comprehensive health
science center; eight state agencies, including the Texas Division
of Emergency Management; and the RELLIS Campus. The Texas A&M
System educates more than 151,000 students and makes more than 22
million additional educational contacts through service and
outreach programs each year. System-wide, research and development
expenditures exceeded $1 billion in FY 2019 and helped drive the
state’s economy.
FORWARD-LOOKING
STATEMENTSSTATEMENTS INCLUDED IN THIS NEWS RELEASE RELATED
TO IBIO, INC. MAY CONSTITUTE FORWARD-LOOKING STATEMENTS WITHIN THE
MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995.
SUCH STATEMENTS INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES SUCH AS
COMPETITIVE FACTORS, TECHNOLOGICAL DEVELOPMENT, MARKET DEMAND, AND
THE COMPANY'S ABILITY TO OBTAIN NEW CONTRACTS AND ACCURATELY
ESTIMATE NET REVENUES DUE TO VARIABILITY IN SIZE, SCOPE, AND
DURATION OF PROJECTS. FURTHER INFORMATION ON POTENTIAL RISK FACTORS
THAT COULD AFFECT THE COMPANY'S FINANCIAL RESULTS CAN BE FOUND IN
THE COMPANY'S REPORTS FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION.
Contacts:
Stephen KilmeriBio, Inc.Investor Relations(646)
274-3580 skilmer@ibioinc.com
The Fearey GroupPublic Relations for
IDRIIDRI@feareygroup.com
iBio (AMEX:IBIO)
Historical Stock Chart
From Feb 2024 to Mar 2024
iBio (AMEX:IBIO)
Historical Stock Chart
From Mar 2023 to Mar 2024